

A catalytic highly enantioselective direct synthesis of 2-bromo-2-nitroalkan-1-ols through a Henry reaction

Gonzalo Blay, * Victor Hernández-Olmos and José R. Pedro*

Departament de Química Orgànica, Facultat de Química, Universitat de València, Dr. Moliner 50, E-46100-Burjassot (València), Spain

General Experimental Methods: Commercial reagents were used as purchased. Glassware was oven-dried overnight at 120 °C. Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-254 thin layer plates. Flash column chromatography was performed on Merck silica gel 60, 0.040-0.063 mm. Specific optical rotations were recorded on a Perkin-Elmer 241 polarimeter using sodium light (D line 589 nm). ¹H NMR were run at 300 MHz for ¹H and at 75 MHz for ¹³C NMR spectra were recorded on Bruker Advance spectrometers in the deuterated solvents as stated, using residual non-deuterated solvent as internal standard. *J* values are given in Hz. The carbon type was determined by DEPT experiments. Mass spectra were recorded on a Fisons Instruments VG Autospec GC 8000 series. Mass spectra (EI) were run at 70 eV. Mass spectra (FAB) were carried out at 30 kV in a MNBA matrix. Chiral HPLC analyses were performed in a Hitachi Elite Lachrom instrument equipped with a Hitachi UV diode-array L-4500 detector using chiral stationary columns from Daicel.


IMPORTANT: Throughout this supporting information, for the stereochemical description of compounds **4**, i. e. (1*S*, 2*R*), 1 always refers to the C-OH carbon and 2 always refers to the C-NO₂ carbon, regardless of the numbering of these carbons in the systematic name of the compound.

General procedure for the enantioselective addition of bromonitromethane to aldehydes. A solution of amino pyridine **1** (6.7 mg, 0.025 mmol) in absolute ethanol (2 mL) was added to Cu(OAc)₂·H₂O (5.0 mg, 0.025 mmol) contained in a Schlenk tube under nitrogen. The mixture was stirred for 1 h at room temperature until the formation of a deep blue solution. The aldehyde **2** (0.5 mmol) was added and the reaction flask introduced in a bath at the reaction temperature. After 5 min, 90% pure technical


bromonitromethane (**3**, 0.39 mL, 5 mmol) was added and the reaction mixture was stirred until completion (TLC). The mixture was treated with 1M aqueous HCl (15 mL) and extracted with dichloromethane (3×15 mL). The organic layer was washed with brine (20 mL), dried over MgSO_4 and concentrated under reduced pressure to give product **4**. For the reactions with additional base, the same procedure was followed, the base being added just after the addition of bromonitromethane.

General procedure for the synthesis of racemic bromonitroalkanols **4.** In a test tube were successively added ethanol (1 mL), aldehyde **2** (0.25 mmol), 90% pure technical bromonitromethane (**3**, 0.195 mL, 2.5 mmol) and DIPEA (87.1 μL , 0.5 mmol). The reaction mixture was stirred at room temperature. The racemic products were isolated following the usual work up.


Determination of the absolute configuration of compound **4a**.



A solution of a 65:35 *anti/syn* mixture of **4a** (50 mg, 0.2 mmol, 79% ee for the *anti* isomer, 80% ee for the *syn* isomer), Bu_3SnH (65 μL , 0.24 mmol) and AIBN (6.7 mg, 0.04 mmol) in dry benzene (1.5 mL) contained in a quartz tube was deoxygenated by bubbling nitrogen for 5 min. The solution was then irradiated with a UV lamp under nitrogen for 7 h. The solvent was removed under reduced pressure and the residue chromatographed on silica gel eluting with hexane:diethyl ether (from 95:5 to 85:15) to give 33.9 mg (99%) of *(S)*-**5**. Compound **5** was obtained in 80% ee as determined by HPLC (Chiralcel OD-H), hexane:*i*-PrOH 90:10, 1 mL/min, major enantiomer *(S)* $t_r = 15.8$, minor enantiomer *(R)* $t_r = 13.5$. The absolute stereochemistry of *(S)*-**5** was assigned by comparison of its spectral features, optical rotation sign and retention times in HPLC with those of an authentic sample of *(S)*-**5**.¹




Lower-energy conformation for *anti*-4a



Lower-energy conformation for *syn*-4a

Conformational energies were minimized using the MM2 force field implemented in the Chem3D Pro program


2-Bromo-2-nitro-1-phenylethanol (4a)²



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 60:40) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralcel OD-H), hexane:*i*-PrOH 90:10, 1 mL/min, *anti*_{major}(1*S*, 2*S*) t_r = 11.7 min, *anti*_{minor}(1*R*, 2*R*) t_r = 10.4 min, *syn*_{major}(1*S*, 2*R*) t_r = 17.4 min, *syn*_{minor}(1*R*, 2*S*) t_r = 12.7 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 7.43 (5 H, s, CH aromatic), 5.95 (1 H, d, J = 9.0, CHBr), 5.31 (1 H, d, J = 9.0, CHOH) and 2.21 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 136.0 (C), 129.8 (CH), 128.9 (2 x CH), 127.3 (2x CH), 81.0 (CH) and 76.3 (CH); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 7.40 (5 H, s, CH aromatic), 6.07


(1 H, d, $J = 4.9$, CHBr), 5.36 (1 H, d, $J = 4.9$, CHO) and 2.21 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 135.8 (C), 129.5 (CH), 128.9 (2 x CH), 126.4 (2 x CH), 85.5 (CH) and 74.6 (CH); m/z (EI) 247 (0.8 %), 245 (M⁺, 0.8), 107 (91), 106 (93), 105 (96) and 77 (100); HRMS 244.9686 (M⁺), C₈H₈BrNO₃ requires 244.9688.

2-Bromo-2-nitro-1-*o*-tolylethanol (**4b**)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 16:84) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak IC), hexane:*i*-PrOH 98:2, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 15.3 min, *anti*_{minor}(1*R*, 2*R*) t_r = 13.9 min, *syn*_{major}(1*S*, 2*R*) t_r = 14.5 min, *syn*_{minor}(1*R*, 2*S*) t_r = 12.8 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 7.39-7.37 (1 H, m, CH aromatic), 7.21-7.16 (3 H, m, CH aromatic), 6.03 (1 H, d, $J = 9.0$, CHBr), 5.63 (1 H, d, $J = 9.0$, CHO), 2.96 (1 H, br s, OH) and 2.50 (3 H s, CH₃); δ_C (75.5 MHz, CDCl₃) 136.6 (C), 134.6 (C), 131.1 (CH), 129.5 (CH), 126.9 (CH), 126.1 (CH), 80.7 (CH), 72.1 (CH) and 19.7 (CH₃); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 7.55-7.49 (1 H, m, CH aromatic), 7.31-7.25 (3 H, m, CH aromatic), 6.11 (1 H, d, $J = 4.8$, CHBr), 5.58 (1 H, d, $J = 4.8$, CHO), 2.96 (1 H, br s, OH) and 2.39 (3 H s, CH₃); δ_C (75.5 MHz, CDCl₃) 135.0 (C), 134.1 (C), 131.0 (CH), 129.3 (CH), 126.7 (CH), 126.6 (CH), 84.7 (CH), 71.4 (CH) and 19.0 (CH₃); m/z (EI) 261 (7.9 %), 259 (M⁺, 7.9), 121 (67), 120 (100), 119 (95) and 91 (85); HRMS 258.9832 (M⁺), C₉H₁₀BrNO₃ requires 258.9844.


2-Bromo-1-(2-methoxyphenyl)-2-nitroethanol (**4c**)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 21:79) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak AD-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 28.0 min, *anti*_{minor}(1*R*, 2*R*) t_r = 25.3 min, *syn*_{major}(1*S*, 2*R*) t_r = 20.1 min, *syn*_{minor}(1*R*, 2*S*) t_r = 24.3


min. *anti isomer* (*1S, 2S*): δ_{H} (300 MHz, CDCl₃) 7.44-7.30 (2 H, m, CH aromatic), 7.05-6.90 (2 H, m, CH aromatic), 6.31 (1 H, d, *J* = 8.7, CHBr), 5.26 (1 H, t, *J* = 8.7, CHOH), 3.94 (3 H, s, OMe) and 3.43 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) δ 156.8 (C), 130.8 (CH), 128.6 (CH), 123.2 (C), 121.3 (CH), 111.0 (CH), 79.6 (CH), 76.1 (CH) and 55.5 (CH₃); *syn isomer* (*1S, 2R*): δ_{H} (300 MHz, CDCl₃) 7.44-7.30 (2 H, m, CH aromatic), 7.05-6.90 (2 H, m, CH aromatic), 6.40 (1 H, d, *J* = 3.9, CHBr), 5.54 (1 H, unresolved t, CHOH), 3.90 (3 H, s, OMe) and 3.43 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 155.7 (C), 130.3 (CH), 128.5 (CH), 124.0 (C), 121.1 (CH), 110.5 (CH), 84.3 (CH), 71.5 (CH) and 55.5 (CH₃); *m/z* (EI) 277 (2.6 %), 275 (M⁺, 2.8), 137 (59), 136 (100), 135 (54) and 77 (71); HRMS 274.9792 (M⁺), C₉H₁₀BrNO₄ requires 274.9793.

2-Bromo-1-(2-chlorophenyl)-2-nitroethanol (**4d**)³




Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 13:87) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralpak AS-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(*1S, 2S*) t_r = 17.2 min, *anti*_{minor}(*1R, 2R*) t_r = 18.3 min, *syn*_{major}(*1S, 2R*) t_r = 12.8 min, *syn*_{minor}(*1R, 2S*) t_r = 13.8 min. *anti isomer* (*1S, 2S*): δ_{H} (300 MHz, CDCl₃) 7.70-7.67 (1 H, m, CH aromatic), 7.42-7.30 (3 H, m, CH aromatic), 6.22 (1 H, d, *J* = 7.5, CHBr), 5.76 (1 H, d, *J* = 7.5, CHOH) and 3.53 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 133.7 (C), 133.0 (C), 130.6 (CH), 130.0 (CH), 128.5 (CH), 127.6 (CH), 80.0 (CH) and 72.8 (CH); *syn isomer* (*1S, 2R*): δ_{H} (300 MHz, CDCl₃) 7.70-7.67 (1 H m, CH aromatic), 7.42-7.30 (3 H, m, CH aromatic), 6.38 (1 H, d, *J* = 2.4, CHBr), 5.84 (1 H, d, *J* = 2.4, CHOH) and 3.53 (1 H, br s, OH). δ_{C} (75.5 MHz, CDCl₃) 133.9 (C), 131.3 (C), 130.3 (CH), 129.5 (CH), 127.3 (CH), 84.4 (CH) and 70.6 (CH); *m/z* (EI) 281 (1.0 %), 279 (M⁺, 0.8), 141 (74), 140 (72), 139 (100) and 111 (36). HRMS 278.9291 (M⁺), C₈H₇BrClNO₃ requires 278.9298.

2-Bromo-2-nitro-1-(2-nitrophenyl)ethanol (**4e**)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 21:79) were determined by ^1H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralpak AS-H), hexane:*i*-PrOH 90:10, 1 mL/min. *anti*_{major}(*1S, 2S*) t_r = 21.4 min, *anti*_{minor}(*1R, 2R*) t_r = 23.1 min, *syn*_{major}(*1S, 2R*) t_r = 17.7 min, *syn*_{minor}(*1R, 2S*) t_r = 19.4 min. *anti isomer* (*1S, 2S*): δ_{H} (300 MHz, CDCl₃) 8.11-7.56 (4 H, m, CH aromatic), 6.35 (1 H d, J = 6.3, CHBr), 5.96 (1 H, d, J = 6.3, CHOH) and 3.75 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 147.9 (C), 134.1 (CH), 131.4 (C), 130.4 (CH), 129.5 (CH), 125.3 (CH), 81.0 (CH) and 72.1 (CH); *syn isomer* (*1S, 2R*): δ_{H} (300 MHz, CDCl₃) 8.11 (1 H, dd, J = 8.4, 1.2, CH aromatic), 8.03 (1 H, d, J = 8.4, CH aromatic), 7.78 (1 H, td, J = 8.4, 1.2, CH aromatic), 7.59 (1 H, td, J = 8.4, 1.2, CH aromatic), 6.55 (1 H, d, J = 2.1, CHBr), 6.10 (1 H, d, J = 2.1, CHOH) and 3.64 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 146.8 (C), 134.2 (CH), 132.3 (C), 130.5 (CH), 130.1 (CH), 125.0 (CH), 84.7 (CH) and 69.1 (CH); *m/z* (EI) 246 (1.7 %), 244 ([M-NO₂]⁺, 2.1), 152 (100), 121 (48), 104 (36), 65 (36); HRMS 243.9614 [M-NO₂]⁺, C₈H₇BrNO₃ requires 243.9610.


2-Bromo-2-nitro-1-m-tolylethanol (**4f**)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 32:68) were determined by ^1H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralpak AD-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(*1S, 2S*) t_r = 15.5 min, *anti*_{minor}(*1R, 2R*) t_r = 14.0 min, *syn*_{major}(*1S, 2R*) t_r = 18.1 min, *syn*_{minor}(*1R, 2S*) t_r = 16.3 min. *anti isomer* (*1S, 2S*): δ_{H} (300 MHz, CDCl₃) 7.33-7.16 (4 H, m, CH aromatic), 5.94 (1 H, d, J = 9.0, CHBr) 5.24 (1 H, d, J = 9.0, CHOH), 3.07 (1 H, br s, OH) and 2.38 (3 H, s, CH₃); δ_{C} (75.5 MHz, CDCl₃) 138.8 (C), 136.0 (C), 130.5 (CH), 128.8 (CH), 127.8 (CH), 124.5 (CH), 81.0 (CH), 76.3 (CH) and 21.4 (CH₃); *syn isomer* (*1S, 2R*): δ_{H} (300 MHz, CDCl₃) 7.33-7.16 (4 H, m, CH aromatic), 6.06 (1 H, d, J = 5.1, CHBr) 5.30 (1 H,


d, $J = 5.1$, CHOH), 3.07 (1 H, br s, OH) and 2.36 (3 H, s, CH₃); δ_{C} (75.5 MHz, CDCl₃) 138.8 (C), 135.8 (C), 130.3 (CH), 128.8 (CH), 127.0 (CH), 123.5 (CH), 85.5 (CH), 74.7 (CH) and 21.4 (CH₃); m/z (EI) 261 (3.2 %), 259 (M⁺, 3.5), 121 (77), 119 (58), 91 (100). HRMS 258.9839 (M⁺), C₉H₁₀BrNO₃ requires 258.9844.

2-Bromo-1-(3-methoxyphenyl)-2-nitroethanol (4g)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 61:39) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldpak AS-H), hexane:*i*-PrOH 90:10, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 14.0 min, *anti*_{minor}(1*R*, 2*R*) t_r = 16.6 min, *syn*_{major}(1*S*, 2*R*) t_r = 17.7 min, *syn*_{minor}(1*R*, 2*S*) t_r = 21.7 min. *anti isomer* (1*S*, 2*S*): δ_{H} (300 MHz, CDCl₃) 7.33 (1 H, t, $J = 8.1$, CH aromatic), 7.01-6.88 (3 H, m, CH aromatic), 5.94 (1 H, d, $J = 9.0$, CHBr), 5.24 (1 H, d, $J = 9.0$, CHOH), 3.82 (3 H, s, OMe) and 3.23 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 159.8 (C), 137.5 (C), 130.0 (CH), 119.6 (CH), 115.1 (CH), 112.9 (CH), 80.9 (CH), 76.2 (CH) and 55.3 (CH₃); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 7.30 (1 H, t, $J = 8.1$, CH aromatic), 7.01-6.88 (3 H, m, CH aromatic), 6.07 (1 H, d, $J = 4.8$, CHBr) 5.32 (1 H, d, $J = 4.8$, CHOH), 3.80 (3 H, s, OMe) and 3.23 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 159.8 (C), 137.5 (C), 118.6 (CH), 114.9 (CH), 112.1 (CH), 85.5 (CH), 74.5 (CH) and 55.3 (CH₃); m/z (EI) 277 (3.7 %), 275 (M⁺, 3.7), 136 (100), 135 (89), 107 (29) and 77 (35). HRMS 274.9804 (M⁺), C₉H₁₀BrNO₄ requires 274.9793.


2-Bromo-1-(3-chlorophenyl)-2-nitroethanol (4h)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 41:59) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldpak AS-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 16.3 min, *anti*_{minor}(1*R*, 2*R*) t_r = 17.8 min, *syn*_{major}(both enantiomers) t_r = 23.1 min. *anti isomer* (1*S*,


2*S*): δ_{H} (300 MHz, CDCl₃) 7.44-7.25 (4 H, m, CH aromatic), 5.90 (1 H, d, *J* = 9.0, CHBr), 5.29 (1 H, d, *J* = 9.0, CHO) and 3.22 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 137.9 (C), 134.8 (C), 130.2 (CH), 129.9 (CH), 127.5 (CH), 125.7 (CH), 80.6 (CH) and 75.6 (CH); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 7.44-7.25 (4 H, m, CH aromatic), 6.05 (1 H, d, *J* = 4.5, CHBr) 5.36 (1 H, d, *J* = 4.5, CHO), 3.22 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 137.9 (C), 134.9 (C), 130.2 (CH), 129.7 (CH), 126.7 (CH), 124.6 (CH), 85.3 (CH) and 73.8 (CH); *m/z* (EI) 281 (5.1 %), 279 (M⁺, 4.4), 141 (100), 140 (69), 139 (91), 125 (39), 111 (48) and 77 (44); HRMS 278.9293 (M⁺), C₈H₇BrClNO₃ requires 278.9298.

2-Bromo-2-nitro-1-(3-nitrophenyl)ethanol (**4i**)⁴




Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 40:60) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralpak AS-H), hexane:*i*-PrOH 90:10, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 22.5 min, *anti*_{minor}(1*R*, 2*R*) t_r = 24.3 min, *syn*_{major}(1*S*, 2*R*) t_r = 36.1 min, *syn*_{minor}(1*R*, 2*S*) t_r = 32.8 min. *anti isomer* (1*S*, 2*S*): δ_{H} (300 MHz, CDCl₃) 8.32 (1H, m, CH aromatic), 8.22 (1H, m, CH aromatic), 7.78 (1H, dd, *J* = 8.1, 3.0, CH aromatic), 7.61 (1H, m, CH aromatic), 5.96 (1 H, d, *J* = 8.7, CHBr), 5.48 (1 H, d, *J* = 8.7, CHO) and 3.87 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 148.2 (C), 138.2 (C), 133.7 (CH), 129.9 (CH), 124.4 (CH), 122.5 (CH), 80.5 (CH) and 75.1 (CH); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 8.32 (1H, m, CH aromatic), 8.22 (1H, m, CH aromatic), 7.78 (1H, dd, *J* = 8.1, 3.0, CH aromatic), 7.61 (1H, m, CH aromatic), 6.16 (1 H, d, *J* = 4.2, CHBr), 5.58 (1 H, d, *J* = 4.2, CHO) and 3.76 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 148.3 (C), 138.4 (C), 132.6 (CH), 129.9 (CH), 124.2 (CH), 121.7 (CH), 85.2 (CH) and 73.3 (CH); *m/z* (EI) 272 ([M-H₂O]⁺, 0.5 %), 151 (100), 150 (80), 105 (42), 95 (40), 93 (43) and 77 (58); HRMS 271.9438 [M-H₂O]⁺, C₈H₅BrN₂O₃ requires 271.9433.

2-Bromo-2-nitro-1-p-tolylethanol (4j)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 70:30) were determined by ^1H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralcel OD-H), hexane:*i*-PrOH 95:5, 0.5 mL/min. *anti_{major}*(1*S*, 2*S*) t_r = 33.7 min, *anti_{minor}*(1*R*, 2*R*) t_r = 35.7 min, *syn_{major}*(1*S*, 2*R*) t_r = 53.2 min, *syn_{minor}*(1*R*, 2*S*) t_r = 41.4 min. *anti isomer* (1*S*, 2*S*): δ_{H} (300 MHz, CDCl₃) 7.33-7.17 (4 H, m, CH aromatic), 5.93 (1 H, d, J = 9.0, CHBr), 5.24 (1 H, d, J = 9.0, CHO), 3.20 (1 H, br s, OH) and 2.37 (3 H, s, CH₃); δ_{C} (75.5 MHz, CDCl₃) 139.7 (C), 133.1 (C), 129.6 (2 x CH), 127.2 (2 x CH), 81.1 (CH), 76.1 (CH) and 21.2 (CH₃); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 7.33-7.17 (4 H, m, CH aromatic), 6.03 (1 H, d, J = 5.4, CHBr), 5.28 (1 H, d, J = 5.4, CHO), 3.20 (1 H, br s, OH) and 2.34 (3 H, s, CH₃); δ_{C} (75.5 MHz, CDCl₃) 139.5 (C), 132.9 (C), 129.6 (2 x CH), 126.4 (2 x CH), 85.4 (CH), 74.6 (CH) and 21.2 (CH₃); *m/z* (EI) 261 (1.2 %), 259 (M⁺, 1.2), 120 (84), 119 (100) and 91 (99); HRMS 258.9849 (M⁺), C₉H₁₀BrNO₃ requires 258.9844.


2-Bromo-1-(4-methoxyphenyl)-2-nitroethanol (4k)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 63:37) were determined by ^1H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralcel OD-H), hexane:*i*-PrOH 90:10, 1 mL/min. *anti_{major}*(1*S*, 2*S*) t_r = 14.5 min, *anti_{minor}*(1*R*, 2*R*) t_r = 16.2 min, *syn* (both enantiomers) t_r = 18.5 min. (Chiraldak IC), hexane:*i*-PrOH 90:10, 1 mL/min. *anti*(both enantiomers) t_r = 14.1 min, *syn_{minor}*(1*R*, 2*S*) t_r = 11.6 min, *syn_{major}* (1*S*, 2*R*) t_r = 12.9 min. *anti isomer* (1*S*, 2*S*): δ_{H} (300 MHz, CDCl₃) 7.35-7.29 (2 H, m, CH aromatic), 6.94-6.88 (2 H, m, CH aromatic), 5.92 (1 H, d, J = 8.7, CHBr), 5.26 (1 H, d, J = 8.7, CHO), 3.82 (3 H, s, OMe) and 3.04 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 160.5 (C), 128.6 (2 x CH), 128.1 (C), 114.3 (2 x CH), 81.3 (CH), 75.9 (CH) and 55.3 (CH₃); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 7.35-7.29 (2 H, m, CH aromatic), 6.94-6.88 (2 H, m, CH aromatic), 6.01 (1 H, d, J = 5.7, CHBr), 5.26


(1 H, d, $J = 5.7$, CHOH), 3.80 (3 H, s, OMe) and 3.04 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 160.4 (C), 127.9 (2 x CH), 127.7 (C), 114.3 (2 x CH), 85.2 (CH), 74.5 (CH) and 55.3 (CH₃); m/z (EI) 277 (2.3 %), 275 (M⁺, 2.6), 137 (69), 136 (70), 135 (100) and 77 (41); HRMS 274.9778 (M⁺), C₉H₁₀BrNO₄ requires 274.9793.

2-Bromo-1-(4-chlorophenyl)-2-nitroethanol (4l)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 69:31) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralcel OD-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 18.9 min, *anti*_{minor}(1*R*, 2*R*) t_r = 25.2 min, *syn*_{major}(1*S*, 2*R*) t_r = 29.4 min, *syn*_{minor}(1*R*, 2*S*) t_r = 26.2 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 7.42-7.33 (4 H, m, CH aromatic), 5.89 (1 H, d, $J = 8.7$, CHBr), 5.30 (1 H, d, $J = 8.7$, CHOH) and 3.13 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 135.7 (C), 134.4 (C), 129.1 (2 x CH), 128.7 (2 x CH), 80.8 (CH) and 75.6 (CH); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 7.42-7.33 (4 H, m, CH aromatic), 6.02 (1 H, d, $J = 4.8$, CHBr), 5.35 (1 H, d, $J = 4.8$, CHOH) and 3.13 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 135.5 (C), 134.3 (C), 129.1 (2 x CH), 127.9 (2 x CH), 85.2 (CH) and 73.9 (CH); m/z (EI) 281 (5.0 %), 279 (M⁺, 4.0), 141 (72), 140 (70), 139 (100), 111 (32); HRMS 278.9286 (M⁺), C₈H₇BrClNO₃ requires 278.9298.


2-Bromo-2-nitro-1-(4-nitrophenyl)ethanol (4m)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 64:36) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralpak AS-H), hexane:*i*-PrOH 90:10, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 27.5 min, *anti*_{minor}(1*R*, 2*R*) t_r = 26.1 min, *syn*_{major}(1*S*, 2*R*) t_r = 41.1 min, *syn*_{minor}(1*R*, 2*S*) t_r = 34.9 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 8.26 (2 H, d, $J = 8.7$, CH aromatic), 7.66 (2 H, d, $J = 8.7$ CH aromatic), 5.94 (1 H, d, $J = 8.7$, CHBr) 5.47 (1 H, d, $J = 8.7$, CHOH) and 3.51 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 148.5 (C), 142.8 (C), 128.6 (2


x CH), 123.9 (2 x CH), 80.3 (CH) and 75.1 (CH); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 8.25 (2 H, d, *J* = 8.7, CH aromatic), 7.63 (2 H, d, *J* = 8.7, CH aromatic), 6.12 (1 H, d, *J* = 4.2, CHBr), 5.56 (1 H, d, *J* = 4.2, CHOH) and 3.56 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 148.3 (C), 143.0 (C), 127.6 (2 x CH), 124.0 (2 x CH), 85.0 (CH) and 73.4 (CH); *m/z* (EI) 292 (0.1 %), 290 (M⁺, 0.1), 141 (72), 151 (100), 150 (86) and 77 (47). HRMS 289.9532 (M⁺), C₈H₇BrN₂O₅ requires 289.9538.

2-Bromo-2-nitro-1-(thiophen-2-yl)ethanol (**4n**)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 36:64) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak AD-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(1*S*, 2*S*) t_r = 21.0 min, *anti*_{minor}(1*R*, 2*R*) t_r = 15.6 min, *syn*_{major}(1*S*, 2*R*) t_r = 23.3 min, *syn*_{minor}(1*R*, 2*S*) t_r = 20.0 min. *anti isomer* (1*S*, 2*S*): δ_{H} (300 MHz, CDCl₃) 7.40 (1H, dd, *J* = 5.1, 1.2, CH aromatic), 7.19 (1 H, dd, *J* = 3.6, 0.6, CH aromatic), 7.05 (1 H, dd, *J* = 5.1, 3.6, CH aromatic), 5.99 (1 H, d, *J* = 9.0, CHBr) 5.59 (1 H, d, *J* = 9.0, CHOH), 3.27 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 138.6 (C), 127.7 (CH), 127.1 (CH), 126.7 (CH), 80.9 (CH), 72.3 (CH); *syn isomer* (1*S*, 2*R*): δ_{H} (300 MHz, CDCl₃) 7.37 (1H, dd, *J* = 5.1, 1.2, CH aromatic), 7.08 (1 H, dt, *J* = 3.6, 0.8, CH aromatic), 7.01 (1 H, dd, *J* = 5.1, 3.9, CH aromatic), 6.09 (1 H, d, *J* = 5.1, CHBr), 5.61 (1 H, d, *J* = 5.1, CHOH), 3.27 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 138.5 (C), 127.2 (CH), 127.0 (CH), 126.7 (CH), 84.6 (CH) and 71.5 (CH); *m/z* (EI) 253 (2.7 %), 251 (M⁺, 2.8), 113 (69), 111 (100), 95 (49) and 93 (55); HRMS 250.9258 (M⁺), C₆H₆BrNO₃S requires 250.9252.


2-Bromo-2-nitro-1-(thiophen-3-yl)ethanol (**4o**)



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 32:68) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC


(Chiralpak AD-H), hexane:*i*-PrOH 95:5, 1 mL/min. *anti*_{major}(1*S*, 2*S*) *t*_r = 24.2 min, *anti*_{minor}(1*R*, 2*R*) *t*_r = 18.0 min, *syn*_{major}(1*S*, 2*R*) *t*_r = 25.1 min, *syn*_{minor}(1*R*, 2*S*) *t*_r = 22.8 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 7.43 (1 H, dd, *J* = 3.0, 1.1, CH aromatic), 7.36 (1 H, d, *J* = 3.0, CH aromatic), 7.14 (1 H, dd, *J* = 5.1, 1.2, CH aromatic), 5.96 (1 H, d, *J* = 9.0, CHBr), 5.42 (1 H, d, *J* = 9.0, CHOH) and 3.11 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 137.0 (C), 127.2 (CH), 125.5 (CH), 125.0 (CH), 80.7 (CH) and 72.2 (CH); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 7.40-7.37 (2 H, m, CH aromatic), 7.09 (1 H, dd, *J* = 4.8, 1.5, CH aromatic), 6.08 (1 H, d, *J* = 5.1, CHBr), 5.45 (1 H, d, *J* = 5.1, CHOH) and 3.11 (1 H, br s, OH); δ_C (75.5 MHz, CDCl₃) 137.0 (C), 127.2 (CH), 125.0 (CH), 124.2 (CH), 84.7 (CH) and 71.5 (CH); *m/z* (EI) 253 (11.2 %), 251 (M⁺, 11.3), 113 (100), 111 (45), 97 (39); HRMS 250.9245 (M⁺), C₆H₆BrNO₃S requires 250.9252.

1-Bromo-1-nitroundecan-2-ol (4p)




Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 54:46) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiralpak AD-H), hexane:*i*-PrOH 99:1, 1 mL/min. (CAUTION, for the stereochemical notation, see page 1 of SI) *anti*_{major}(1*S*, 2*S*) *t*_r = 27.9 min, *anti*_{minor}(1*R*, 2*R*) *t*_r = 18.4 min, *syn*_{major}(1*S*, 2*R*) *t*_r = 20.8 min, *syn*_{minor}(1*R*, 2*S*) *t*_r = 18.9 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 5.75 (1 H, d, *J* = 8.1, CHBr), 4.26-4.17 (1 H, m, CHOH), 2.61 (1 H, br s, OH), 1.66-1.48 (2 H, m, CH₂CHOH), 1.26 (14 H, m, 7 x CH₂) and 0.88 (3 H, t, *J* = 6.6, CH₃); δ_C (75.5 MHz, CDCl₃) 81.6 (CH), 73.3 (CH), 33.7 (CH₂), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 25.1 (CH₂), 22.6 (CH₂) and 14.1 (CH₃); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 5.98 (1 H, d, *J* = 3.3, CHBr), 4.26-4.17 (1 H, m, CHOH), 2.73 (1 H, br s, OH), 1.66-1.48 (2 H, m, CH₂CHOH), 1.26 (14 H, m, 7 x CH₂) and 0.87 (3 H, t, *J* = 6.6, CH₃); δ_C (75.5 MHz, CDCl₃) 86.3 (CH), 72.6 (CH), 32.0 (CH₂), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 24.9 (CH₂), 22.6 (CH₂) and 14.1 (CH₃); *m/z* (EI) 216 ([M-Br]⁺, 2.5 %), 95 (67), 82 (73), 81 (66), 69 (81), 57 (80), 55 (100); HRMS 216.1593 [M-Br]⁺, C₁₁H₂₂NO₃ requires 216.1600.

1-Bromo-1-nitro-4-phenylbutan-2-ol (4q)⁵



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 54:46) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak AD-H), hexane:*i*-PrOH 95:5, 1 mL/min. (CAUTION, for the stereochemical notation, see page 1 of SI) *anti*_{major}(1*S*, 2*S*) t_r = 20.3 min, *anti*_{minor}(1*R*, 2*R*) t_r = 15.9 min, *syn*_{major}(1*S*, 2*R*) t_r = 23.7 min, *syn*_{minor}(1*R*, 2*S*) t_r = 21.6 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 7.24-7.18 (5 H, m, CH aromatic), 5.76 (1 H, d, J = 7.8, CHBr), 4.26-4.19 (1 H, m, CHOH) 2.98-1.78 (5 H, m, 2 x CH₂ + OH); δ_C (75.5 MHz, CDCl₃) 140.3 (C), 128.7 (2 x CH), 128.4 (2 x CH), 126.4 (CH), 81.4 (CH), 72.6 (CH), 33.5 (CH₂) and 31.1 (CH₂); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 7.34-7.31 (5 H, m, CH aromatic), 5.94 (1 H, d, J = 3.3, CHBr), 4.26-4.19 (1 H, m, CHOH) and 2.98-1.78 (5 H, m, 2 x CH₂ + OH); δ_C (75.5 MHz, CDCl₃) 140.1 (C), 128.7 (2 x CH), 128.4 (2 x CH), 126.4 (CH), 85.9 (CH), 71.6 (CH), 35.1 (CH₂) and 31.2 (CH₂); *m/z* (EI) 275 (0.2 %), 273 (M⁺, 0.3), 134 (36), 92 (39), 91 (100); HRMS 272.9997 (M⁺), C₁₀H₁₂BrNO₃ requires 273.0001.


1-Bromo-4-methyl-1-nitropentan-2-ol (4r)¹



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 57:43) were determined by ¹H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak AD-H), hexane:*i*-PrOH 98:2, 1 mL/min. (CAUTION, for the stereochemical notation, see page 1 of SI) *anti*_{major}(1*S*, 2*S*) t_r = 21.1 min, *anti*_{minor}(1*R*, 2*R*) t_r = 16.0 min, *syn*_{major}(1*S*, 2*R*) t_r = 17.3 min, *syn*_{minor}(1*R*, 2*S*) t_r = 18.3 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, CDCl₃) 5.73 (1 H, d, J = 7.8, CHBr), 4.31-4.25 (1 H, m, CHOH), 2.50 (1 H, br s, OH), 1.96-1.77 (1 H, m, CH(CH₃)₂), 1.63-1.42 (1 H, m, CH₂), 1.35-1.25 (1 H, m, CH₂) and 0.97 (6 H, t, J = 6.9, 2 x CH₃); δ_C (75.5 MHz, CDCl₃) 82.1(CH), 71.9 (CH), 40.8 (CH₂), 24.4 (CH), 23.5 (CH₃) and 21.2 (CH₃); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, CDCl₃) 5.96 (1 H, d, J = 3.3, CHBr), 4.31-4.25 (1 H, m, CHOH), 2.60 (1 H, br s, OH),


1.96-1.77 (1 H, m, $CH(CH_3)_2$), 1.63-1.42 (2 H, m, CH_2), 0.97 (6 H, t, $J = 6.9$, 2 x CH_3); δ_C (75.5 MHz, $CDCl_3$) 86.5 (CH), 71.0 (CH), 42.4 (CH_2), 24.4 (CH), 23.0 (CH_3) and 21.7 (CH_3); m/z (EI) 146 ([M-Br] $^+$, 0.9 %), 87 (77), 81 (76), 69 (100); HRMS 146.0818 [M-Br] $^+$, $C_6H_{12}NO_3$ requires 146.0817.

2-Bromo-1-cyclohexyl-2-nitroethanol (4s)¹



Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 66:34) were determined by 1H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak AD-H), hexane:*i*-PrOH 95:5, 1 mL/min. (CAUTION, for the stereochemical notation, see page 1 of SI) *anti*_{major}(1*S*, 2*S*) t_r = 10.3 min, *anti*_{minor}(1*R*, 2*R*) t_r = 9.3 min, *syn*_{major}(1*S*, 2*R*) t_r = 17.9 min, *syn*_{minor}(1*R*, 2*S*) t_r = 14.4 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, $CDCl_3$) 5.85 (1 H, d, $J = 8.4$, CHBr), 4.07 (1 H, dd, $J = 8.4$, 3.3, CHOH), 2.58 (1 H, br s, OH) and 2.07-1.05 (11 H, m, Cy); δ_C (75.5 MHz, $CDCl_3$) 79.8 (CH), 76.8 (CH), 38.5 (CH), 29.9 (CH_2), 26.0 (CH_2), 25.9 (CH_2), 25.6 (CH_2) and 24.9 (CH_2); *syn isomer* (1*S*, 2*R*): δ_H (300 MHz, $CDCl_3$) 6.14 (1 H, d, $J = 3.0$, CHBr), 3.92 (1 H, dd, $J = 7.8$, 2.7, CHOH), 2.58 (1 H, br s, OH) and 2.07-1.05 (10 H, m, Cy); δ_C (75.5 MHz, $CDCl_3$) 86.0 (CH), 76.7 (CH), 41.4 (CH), 28.6 (CH_2), 28.3 (CH_2), 25.9 (CH_2), 25.5 (CH_2) and 25.4 (CH_2); m/z (EI) 172 ([M-Br] $^+$, 3.4 %), 95 (43), 83 (100), 55 (27); HRMS 172.0981 [M-Br] $^+$, $C_8H_{14}NO_3$ requires 172.0970.

(E)-1-Bromo-1-nitro-4-phenylbut-3-en-2-ol (4t)






Purified according to the general procedure. Diastereomeric ratios (*anti/syn*, 32:68) were determined by 1H NMR. Enantiomeric excesses were determined by chiral HPLC (Chiraldak AS-H), hexane:*i*-PrOH 95:5, 1 mL/min. (CAUTION, for the stereochemical notation, see page 1 of SI) *anti*_{major}(1*S*, 2*S*) t_r = 20.9 min, *anti*_{minor}(1*R*, 2*R*) t_r = 22.9 min, *syn*_{major}(1*S*, 2*R*) t_r = 28.9 min, *syn*_{minor}(1*R*, 2*S*) t_r = 31.0 min. *anti isomer* (1*S*, 2*S*): δ_H (300 MHz, $CDCl_3$) 7.42-7.27 (5 H, m, CH aromatic), 6.83 (1 H, d, $J = 15.9$, CH

olephinic), 6.17 (1 H, dd, $J = 15.9, 6.9$, CH olephinic), 5.84 (1 H, d, $J = 8.1$, CHBr), 4.97-4.92 (1 H, m, CHOH), 2.94 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 136.2 (CH), 135.2 (C), 128.8 (CH), 128.7 (2 x CH), 126.9 (2 x CH), 122.6 (CH), 80.8 (CH), 74.4 (CH); *syn isomer* (*1S, 2R*): δ_{H} (300 MHz, CDCl₃) 7.42-7.27 (5 H, m, CH aromatic), 6.78 (1 H, d, $J = 15.9$, CH olephinic), 6.12 (1 H, dd, $J = 15.9, 6.6$, CH olephinic), 6.03 (1 H, d, $J = 4.2$, CHBr), 4.97-4.92 (1 H, m, CHOH), 2.94 (1 H, br s, OH); δ_{C} (75.5 MHz, CDCl₃) 135.7 (CH), 135.1 (C), 128.8 (CH), 128.7 (2 x CH), 126.9 (2 x CH), 123.0 (CH), 84.6 (CH), 73.9 (CH); *m/z* (EI) 273 (0.4 %), 271 (M⁺, 0.4), 132 (71), 131 (100), 103 (58) and 77 (48). HRMS 278.9841 (M⁺), C₁₀H₁₀BrNO₃ requires 270.9844.


REFERENCES



1. G. Blay, L. R. Domingo, V. Hernández-Olmos, J. R. Pedro, *Chem. Eur. J.*, 2008, **14**, 4725.
2. J. M. Concellon, H. Rodriguez-Solla, C. Concellon, S. Garcia-Granda, M. R.; Diaz, *Org. Lett.*, 2006, **8**, 5979.
3. *Jpn. pat.*, JP 54141738, 1979.
4. *Jpn. pat.*, JP 50117933, 1975.
5. R. Ballini, G. Bosica, P. Forconi, *Tetrahedron*, 1996, **52**, 1677.
6. *Jpn. pat.*, JP 60048903, 1985








4b









4c










4d
















4g















4j







4k








4l











4n















4p

















RT	Area	Area %
10.11	7856702	34.474
11.61	8071981	35.418
12.65	3326170	14.595
17.58	3535573	15.513
	22790426	100.000




RT	Area	Area %
10.40	298687	1.687
11.67	10453622	59.045
12.65	305911	1.728
17.35	6646234	37.540
	17704454	100.000




RT	Area	Area %
12.77	2850984	11.430
13.88	9371720	37.572
14.61	2405210	9.643
15.29	10315285	41.355
	24943199	100.000




RT	Area	Area %
12.79	188400	1.679
13.89	26266	0.234
14.46	8419500	75.034
15.25	2586710	23.053
	11220876	100.000




RT	Area	Area %
18.15	9847357	25.698
21.46	9005557	23.501
22.37	9820073	25.626
24.55	9647083	25.175
	38320070	100.000




RT	Area	Area %
20,13	11440944	76,815
24,29	281213	1,888
25,25	96752	0,650
28,00	3075151	20,647
	14894060	100,000




RT	Area	Area %
12.28	8339343	20.956
13.16	8618850	21.658
16.26	10671959	26.817
17.15	12164827	30.569
	39794979	100.000




RT	Area	Area %
12.80	9152913	85.717
13.75	149932	1.404
17.23	1335763	12.509
18.25	39425	0.369
	10678033	100.000




RT	Area	Area %
18.22	15758328	23.275
19.52	16236566	23.982
21.97	18083628	26.710
23.37	17625155	26.033
	67703677	100.000




RT	Area	Area %
17.68	17016636	83.816
19.37	312605	1.540
21.62	2800841	13.796
23.11	172254	0.848
	20302336	100.000




RT	Area	Area %
14.12	7750924	33.580
15.64	7592604	32.894
16.49	3936664	17.055
18.60	3801968	16.471
	23082160	100.000




RT	Area	Area %
13.97	158864	0.906
15.46	5414070	30.874
16.27	176089	1.004
18.12	11787076	67.216
	17536099	100.000




RT	Area	Area %
14.68	11294684	33.188
17.31	11183999	32.863
18.99	5779021	16.981
23.29	5774440	16.968
	34032144	100.000




RT	Area	Area %
13.97	10315282	58.904
16.55	324391	1.852
17.67	6650742	37.978
21.73	221497	1.265
	17511912	100.000




RT	Area	Area %
16.55	9977593	33.367
17.81	10050384	33.610
23.70	9874684	33.023
	29902661	100.000





RT	Area	Area %
16.33	13122431	39.428
17.84	382517	1.149
23.05	19777150	59.423
	33282098	100.000





RT	Area	Area %
23.71	6151224	33.707
25.47	6180910	33.869
34.96	2957581	16.207
39.36	2959530	16.217
	18249245	100.000




RT	Area	Area %
22.51	5632666	37.879
24.29	392822	2.642
32.81	287131	1.931
36.07	8557354	57.548
	14869973	100.000





RT	Area	Area %
33.69	26855568	66.369
35.67	1724873	4.263
41.39	490984	1.213
53.24	11392636	28.155
	40464061	100.000




RT	Area	Area %
14.57	5653935	35.424
16.31	5588225	35.012
18.21	2148467	13.461
18.61	2570072	16.103
	15960699	100.000





RT	Area	Area %
14.47	14504713	60.640
16.23	487385	2.038
18.54	8927477	37.323
	23919575	100.000




RT	Area	Area %
11.55	2388671	11.687
12.98	2605482	12.748
13.71	7300508	35.719
14.13	8144121	39.846
	20438782	100.000





RT	Area	Area %
11.58	173345	1.275
12.93	5179010	38.106
14.09	8238613	60.618
	13590968	100.000




RT	Area	Area %
18.01	11058083	40.552
23.17	11737240	43.042
24.67	2477830	9.087
27.95	1995984	7.320
	27269137	100.000





RT	Area	Area %
18.86	14463880	65.568
25.15	775763	3.517
26.24	329947	1.496
29.39	6489843	29.420
	22059433	100.000




RT	Area	Area %
26.25	11874785	37.060
27.70	12349695	38.542
35.34	4051106	12.643
41.81	3766537	11.755
	32042123	100.000





RT	Area	Area %
26.08	4609811	17.987
27.45	11812808	46.093
34.93	2837564	11.072
41.10	6367849	24.847
	25628032	100.000




RT	Area	Area %
16.09	5964060	33.960
20.84	2905158	16.542
21.95	6244848	35.559
24.42	2448081	13.940
	17562147	100.000




RT	Area	Area %
15.57	569666	2.328
19.97	379769	1.552
21.01	9343608	38.181
23.29	14178523	57.939
	24471566	100.000




RT	Area	Area %
18.69	9062719	34.470
23.85	4146759	15.772
25.47	9106867	34.638
26.38	3975051	15.119
	26291396	100.000




RT	Area	Area %
18.02	367739	1.568
22.83	339297	1.447
24.21	8155026	34.778
25.07	14586499	62.206
	23448561	100.000




RT	Area	Area %
19.17	6364936	38.035
21.48	2570024	15.358
22.47	2569561	15.355
28.58	5229702	31.252
	16734223	100.000




RT	Area	Area %
18.37	720154	4.446
18.87	353213	2.181
20.79	7157540	44.192
27.85	7965596	49.181
	16196503	100.000




RT	Area	Area %
13.47	7213232	33.884
16.45	6503222	30.549
17.83	3869203	18.176
19.69	3702214	17.391
	21287871	100.000




RT	Area	Area %
15.89	1099625	3.443
20.31	15961611	49.974
21.62	980224	3.069
23.71	13898432	43.514
	31939892	100.000




RT	Area	Area %
15.97	5571706	32.661
17.30	2948604	17.285
18.29	3179613	18.639
21.23	5359230	31.416
	17059153	100.000




RT	Area	Area %
16.01	626304	3.858
17.26	6750022	41.580
18.27	275041	1.694
21.12	8582453	52.868
	16233820	100.000




RT	Area	Area %
9.22	2837725	31.001
10.27	2743889	29.976
14.67	1800151	19.666
17.67	1771797	19.356
	9153562	100.000



RT	Area	Area %
9.27	292261	3.350
10.34	5480692	62.830
14.41	137133	1.572
17.92	2812896	32.247
	8722982	100.000



RT	Area	Area %
20.10	7933544	32.562
22.02	8009276	32.873
27.64	4178037	17.148
29.62	4243741	17.418
	24364598	100.000



RT	Area	Area %
20.94	9812941	32.509
22.93	1044880	3.462
28.85	18986960	62.901
31.01	340599	1.128
	30185380	100.000